Ajanta Pharma Ltd

Ajanta Pharma Ltd Share Price Today: Live Updates & Key Insights

Get insights on Ajanta Pharma Ltd’s fundamentals, financials, shareholding, peer comparison, corporate actions & performance. Track key metrics, price trends & market sentiment for informed decisions. Explore all data at Motilal Oswal.

Ajanta Pharma Ltd Share Price Chart

Ajanta Pharma Ltd Fundamentals

Traded Volume: 27,168

Market Cap(Cr): 31,055

Avg Traded Price 2483.11

1 Year return -15.61%

Upper Circuit 2,500

Lower Circuit 2,465

P/E TTM 32.00

P/B Ratio 78.00

Traded Value(Cr) 675.31

EPS TTM 77.948

Book value 77.948

Dividend 1.00%

Ajanta Pharma Ltd Share Price Performance

Shows the percentage change in stock price over different time periods

This section highlights Ajanta Pharma Ltd stock price performance across key timeframes, including 1-week, 1-month, 3-month, Year-To-Date (YTD), and 1-year returns. It provides insights into the Ajanta Pharma Ltd share price history, short-term movements, long-term trends, and overall investor sentiment

1W -2.48%

1M +2.03%

3M -7.38%

1Y -15.61%

YTD -16.15%

Ajanta Pharma Ltd Traded Volume Movement

Shows the trading volume over different time periods

This section highlights Ajanta Pharma Ltd daily and average traded volumes, offering insights into investor activity and market liquidity. Higher volumes than average often indicate rising interest, news impact, or shifting market sentiment

Yesterday 22601.00

Day Before Yesterday 54529.00

1W Avg 93430.80

1M Avg 99166.10

3M Avg 1.08L

Ajanta Pharma Ltd Technical Details

Ajanta Pharma Ltd technical indicators, such as support and resistance levels and pivot points, are calculated based on historical price and volume trends. These metrics help traders anticipate possible price movements and make informed trading decisions.

Support 1 2467

Support 2 2449

Support 3 2432

Pivot Point : 2484

Resistance 1 2502

Resistance 2 2519

Resistance 3 2537

Ajanta Pharma Ltd Corporate Actions

Ajanta Pharma Ltd corporate actions include dividends, bonus issues, stock splits, and key company updates that may affect share price and investor sentiment. This section provides timely details on past and upcoming actions, including ex-date, record date, and payout ratio - helping investors make informed decisions based on Ajanta Pharma Ltd’s capital allocation strategies.

All

Ex-Date 10-Nov-2025 Type D Description 28.00/share@1400.00% Record Date 10-Nov-2025 Ratio 1400.00

Ex-Date 06-Nov-2024 Type D Description 28.00/share@1400.00% Record Date 06-Nov-2024 Ratio 1400.00

Ex-Date 30-May-2024 Type T Description /share@% Record Date - Ratio

Ex-Date 08-Feb-2024 Type D Description 26.00/share@1300.00% Record Date 08-Feb-2024 Ratio 1300.00

Ex-Date 04-Aug-2023 Type D Description 15.00/share@750.00% Record Date 04-Aug-2023 Ratio 750.00

Ex-Date 04-Aug-2023 Type D Description 10.00/share@500.00% Record Date 04-Aug-2023 Ratio 500.00

Ex-Date 24-Mar-2023 Type T Description /share@% Record Date - Ratio

Ex-Date 11-Nov-2022 Type D Description 7.00/share@350.00% Record Date 14-Nov-2022 Ratio 350.00

Ex-Date 22-Jun-2022 Type B Description share@1:2 Record Date 23-Jun-2022 Ratio 1:2

Ex-Date 09-Nov-2021 Type D Description 9.50/share@475.00% Record Date 10-Nov-2021 Ratio 475.00

Ex-Date 12-Nov-2020 Type T Description /share@% Record Date - Ratio

Ex-Date 12-Nov-2020 Type D Description 9.50/share@475.00% Record Date 13-Nov-2020 Ratio 475.00

Ex-Date 15-Nov-2019 Type D Description 13.00/share@650.00% Record Date 18-Nov-2019 Ratio 650.00

Ex-Date 11-Feb-2019 Type T Description /share@% Record Date - Ratio

Ex-Date 09-Nov-2018 Type D Description 9.00/share@450.00% Record Date 12-Nov-2018 Ratio 450.00

Ex-Date 23-Mar-2017 Type D Description 7.00/share@350.00% Record Date 25-Mar-2017 Ratio 350.00

Ex-Date 07-Nov-2016 Type D Description 6.00/share@300.00% Record Date 08-Nov-2016 Ratio 300.00

Ex-Date 17-Mar-2016 Type D Description 8.00/share@400.00% Record Date 19-Mar-2016 Ratio 400.00

Ex-Date 25-Jun-2015 Type D Description 6.00/share@300.00% Record Date - Ratio 300.00

Ex-Date 20-Mar-2015 Type S Description share@1:2.50 Record Date 23-Mar-2015 Ratio 1:2.50

Ex-Date 24-Jul-2014 Type D Description 10.00/share@200.00% Record Date - Ratio 200.00

Ex-Date 17-Sep-2013 Type B Description share@1:2 Record Date 18-Sep-2013 Ratio 1:2

Ex-Date 18-Jul-2013 Type D Description 6.25/share@125.00% Record Date - Ratio 125.00

Ex-Date 09-Aug-2012 Type S Description share@1:2.00 Record Date 10-Aug-2012 Ratio 1:2.00

Ex-Date 28-Jun-2012 Type D Description 7.50/share@75.00% Record Date - Ratio 75.00

Ex-Date 23-Jun-2011 Type D Description 5.00/share@50.00% Record Date - Ratio 50.00

Ex-Date 29-Jun-2010 Type D Description 3.50/share@35.00% Record Date - Ratio 35.00

Ex-Date 30-Jun-2009 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 27-Jun-2008 Type D Description 2.50/share@25.00% Record Date - Ratio 25.00

Ex-Date 19-Sep-2007 Type D Description 2.00/share@20.00% Record Date - Ratio 20.00

Dividends

Announcement Date 10-Nov-2025 Ex Dividend Date 10-Nov-2025 Dividend(%) 1400

Announcement Date 06-Nov-2024 Ex Dividend Date 06-Nov-2024 Dividend(%) 1400

Announcement Date 08-Feb-2024 Ex Dividend Date 08-Feb-2024 Dividend(%) 1300

Announcement Date 04-Aug-2023 Ex Dividend Date 04-Aug-2023 Dividend(%) 500

Announcement Date 04-Aug-2023 Ex Dividend Date 04-Aug-2023 Dividend(%) 750

Announcement Date 11-Nov-2022 Ex Dividend Date 11-Nov-2022 Dividend(%) 350

Announcement Date 09-Nov-2021 Ex Dividend Date 09-Nov-2021 Dividend(%) 475

Announcement Date 12-Nov-2020 Ex Dividend Date 12-Nov-2020 Dividend(%) 475

Announcement Date 15-Nov-2019 Ex Dividend Date 15-Nov-2019 Dividend(%) 650

Announcement Date 09-Nov-2018 Ex Dividend Date 09-Nov-2018 Dividend(%) 450

Announcement Date 23-Mar-2017 Ex Dividend Date 23-Mar-2017 Dividend(%) 350

Announcement Date 07-Nov-2016 Ex Dividend Date 07-Nov-2016 Dividend(%) 300

Announcement Date 17-Mar-2016 Ex Dividend Date 17-Mar-2016 Dividend(%) 400

Announcement Date 25-Jun-2015 Ex Dividend Date 25-Jun-2015 Dividend(%) 300

Announcement Date 24-Jul-2014 Ex Dividend Date 24-Jul-2014 Dividend(%) 200

Announcement Date 18-Jul-2013 Ex Dividend Date 18-Jul-2013 Dividend(%) 125

Announcement Date 28-Jun-2012 Ex Dividend Date 28-Jun-2012 Dividend(%) 75

Announcement Date 23-Jun-2011 Ex Dividend Date 23-Jun-2011 Dividend(%) 50

Announcement Date 29-Jun-2010 Ex Dividend Date 29-Jun-2010 Dividend(%) 35

Announcement Date 30-Jun-2009 Ex Dividend Date 30-Jun-2009 Dividend(%) 25

Announcement Date 27-Jun-2008 Ex Dividend Date 27-Jun-2008 Dividend(%) 25

Announcement Date 19-Sep-2007 Ex Dividend Date 19-Sep-2007 Dividend(%) 20

Bonus

Record Date 23-Jun-2022 Ex-Bonus Date 22-Jun-2022 Ratio 1:2

Record Date 18-Sep-2013 Ex-Bonus Date 17-Sep-2013 Ratio 1:2

Splits

Record Date 23-Mar-2015 Split Date 20-Mar-2015 Face Value (Before/After) 5.00/2.00

Record Date 10-Aug-2012 Split Date 09-Aug-2012 Face Value (Before/After) 10.00/5.00

Others

Ex-Rights Date 30-May-2024 Premium(Rs.) Ratio

Ex-Rights Date 24-Mar-2023 Premium(Rs.) Ratio

Ex-Rights Date 12-Nov-2020 Premium(Rs.) Ratio

Ex-Rights Date 11-Feb-2019 Premium(Rs.) Ratio

Ajanta Pharma Ltd Peer Comparison

Shows key financial metrics for the company and its peers

This section compares Ajanta Pharma Ltd with leading peers in the banking sector based on key metrics such as market capitalization, 1-year return, P/E (TTM), and PB ratio. It helps investors evaluate Ajanta Pharma Ltd's relative performance and valuation against major competitors.

Stock Name Glaxosmithkline Pharmaceuticals Ltd ₹2497.90 (-0.44%) M. Cap (Cr) 423.16 1 Yr Return (%) +5.41% P/E (TTM) 44.30 PB Ratio 21.69

Stock Name Ipca Laboratories Ltd ₹1444.00 (+0.40%) M. Cap (Cr) 366.35 1 Yr Return (%) -8.23% P/E (TTM) 44.05 PB Ratio 5.27

Stock Name Anthem Biosciences Ltd ₹635.10 (-1.91%) M. Cap (Cr) 356.68 1 Yr Return (%) NaN% P/E (TTM) 69.10 PB Ratio 14.80

Stock Name Ajanta Pharma Ltd ₹2485.70 (-1.00%) M. Cap (Cr) 310.55 1 Yr Return (%) -15.61% P/E (TTM) 31.89 PB Ratio 8.44

Stock Name Gland Pharma Ltd ₹1809.70 (-0.42%) M. Cap (Cr) 298.16 1 Yr Return (%) +1.27% P/E (TTM) 37.72 PB Ratio 3.26

Stock Name J B Chemicals & Pharmaceuticals Ltd ₹1729.60 (-1.08%) M. Cap (Cr) 270.85 1 Yr Return (%) +1.62% P/E (TTM) 37.71 PB Ratio 8.43

Stock Name Emcure Pharmaceuticals Ltd ₹1354.60 (-0.52%) M. Cap (Cr) 256.78 1 Yr Return (%) NaN% P/E (TTM) 32.38 PB Ratio 6.23

Ajanta Pharma Ltd Cash Flow

Cash flow data provides a view of how money is generated and spent by Ajanta Pharma Ltd, across its operating activities, investing activities, and financing activities.

PARTICULARS Operating Activities Mar 2025 1053.80 Mar 2024 735.35 Mar 2023 736.29 Mar 2022 542.34 Mar 2021 466.99

PARTICULARS Investing Activities Mar 2025 -349.60 Mar 2024 105.02 Mar 2023 -501.31 Mar 2022 -66.04 Mar 2021 -162.68

PARTICULARS Financing Activities Mar 2025 -715.71 Mar 2024 -1047.70 Mar 2023 -105.12 Mar 2022 -457.30 Mar 2021 -268.90

PARTICULARS Net Cash Flow Mar 2025 -11.51 Mar 2024 -207.33 Mar 2023 129.86 Mar 2022 19.00 Mar 2021 35.41

Ajanta Pharma Ltd Shareholding Pattern

This shows the ownership breakdown of Ajanta Pharma Ltd, highlighting participation from Foreign Institutional Investors (FII), Mutual Funds, Public, Other Institutions, and Promoters.

Promoter 66.25%

Public 7.32%

Other Institutions 3.24%

FII 8.53%

Mutual Funds 14.67%

About Ajanta Pharma Ltd

Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa. The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets. It produces a comprehensive range of specialty products targeting different therapeutic segments. It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, the Company has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharma's products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The company's institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been approved by USFDA. The company has an advanced Research & Development Centre in Mumbai for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. Its R&D centre has a team of over 750 scientists working on innovative products for various markets across the globe. Established in 1973 and headquartered in Mumbai-India, the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up its 1stManufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period from 1995 to 1998, the company established dedicated R&D facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000, the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002, the company entered domestic prescription market with speciality segment force. In 2007, the company expanded its R&D facility with independent premises in Kandivali. The company also got USFDA Approval for its Paithan manufacturing facility in 2008. In 2009, the company started Active Pharmaceutical Ingredient (API) plant in Waluj, Aurangabad for captive use. During the year, the company bought a manufacturing facility at Chitegaon in Aurangabad, Maharashtra to fuel the company's growth. Also during the year, Ajanta Pharma became the first generic company in the world to get WHO Geneva Pre-qualification for Anti-Malarial Drug.In 2010, Ajanta Pharma entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc. In 2011, Ajanta Pharma emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions.In 2012, Ajanta Pharma was ranked among the Top 10 pharma companies in Franco Africa. During the year 2013, Ajanta Pharma commenced sales to the US market. In 2014, the company set up its 2nd dedicated R&D centre at Kandivli in Mumbai for India and emerging markets. During the year, the company inaugurated a new facility in Dahej, Bharuch, Gujarat for catering to the requirements of markets like USA, WHO and emerging markets. In 2015, the company announced the launch of Montelukast Sodium Oral Granules. The company also announced the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in US market.In 2017, the company inaugurated and commissioned 1st phase at a new facility in Guwahati, Assam. The company's Dahej, Gujarat facility was approved by the USFDA without any observation in April 2017.On 11 July 2017, Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma (APL) informed the company that promoters have sold 27 lakh equity shares in APL, representing about 3.07% of APL's equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% in APL. This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use.On 9 February 2018, Ajanta Pharma announced that its formulation facility at Dahej in Gujarat was inspected by USFDA from 5 to 9 February 2018. At the end of the inspection, no Form 483 was issued to the company by the USFDA.As on 31 March 2018,the company has six subsidiaries overseas, including one step down subsidiary under its roof.The company's capex investment in manufacturing facilities and R&D which has taken the total from Rs 997 crore in FY 2017 to Rs 1,225 crore in FY 2018.The Company had convened Extra-Ordinary General Meeting on 10th October 2017 as per the directions of National Company Law Tribunal for obtaining consent of shareholders for merger of Gabs Investments Private Ltd. with the Company.During the FY2019, company's wholly owned subsidiary viz., Ajanta Pharma UK Limited was dissolved on 18th December 2018. Post that, the company has five operating subsidiaries overseas, including one step down subsidiary.The total capex for FY 2019 was Rs 361 crore and propose to spend further Rs 350 crore in FY 2020, mainly on Guwahati, Pithampur and corporate office in Mumbai.in March 2019, the Company bought back 7,69,230 (Seven lakhs sixty-nine thousand two hundred and thirty only) fully paidup equity shares of the face value of Rs 2/- each at a price of Rs 1300 per share for an aggregate amount of Rs 100 crore.The Scheme of Amalgamation and Arrangement of Gabs Investments Pvt. Ltd. with the Company which was filed by the Company with National Company Law Tribunal (NCLT) in the last year, was rejected by NCLT on grounds cited in its order. The Company had preferred an appeal before the National Company Law Appellate Tribunal (NCLAT) challenging the order of NCLT. However, after considering all the pros and cons at length, it was deemed appropriate to withdraw the appeal. Accordingly, the same was withdrawn on 7th December 2018.During the FY2020, third phase of Guwahati plant, new manufacturing facility in Pithampur, Madhya Pradesh and new R & D building in Kandivli, Mumbai were completed and became fully functional. Expansion of facility at Dahej has been commenced and the same is expected to be over by December 2020. During the year, an amount of Rs 245 crore was incurred on capex.The Board of Directors have approved buyback proposal on 3 November 2020, for purchase by the Company of up to 7,35,000 shares of Rs 2 each (representing 0.84% of total paid-up equity capital) from the shareholders of the Company on a proportionate basis by way of a tender offer at a price of Rs 1,850 per equity share for an aggregate amount not exceeding Rs 135.98 crore in accordance with the provisions of the Companies Act, 2013 and the SEBI (Buy Back of Securities) Regulations, 2018.During the quarter ended 31 December 2020,the group had bought back its 735000 equity shares of Rs 2/-each at Rs 1850 per share for an aggregate amount of Rs 135.98 crore and extinguished those shares on 30 December 2020.The Company launched 16 new products in FY 2022, including four 1st to market products in the country. During the year 2022, it launched 3 new products and filed 8 ANDAs. It received 2 final and 1 tentative approval. There are 20 ANDAs awaiting approval from US FDA.The Company launched 23 new products in FY 2023 with six first-to-market products.In 2024, Company launched 27 new products. It has expanded the product portfolio with the launching of 25 new products in chronic therapies in 2025.

Chairman (Non-Executive)

Mannalal B Agrawal

Registered office Ajanta House, Charkop Kandivli (W), Mumbai, Maharashtra, 400067

FAX :91-22-66061000/1204/1203

Background

Incorporation Year 1979

Face Value ₹2.00

Market Lot 1

Ajanta Pharma Ltd Latest News

VIEW MORE NEWS

FAQs on Ajanta Pharma Ltd